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Abstract
AIM: Urea breath test (UBT) is a non-invasive diagnostic test
for detecting the presence of Helicobacter pylori (H pylori).
In this study we evaluated the effect of anti-tuberculosis
therapy on the results of 14C-UBT.
METHODS: Patients, with the diagnosis of tuberculosis
(TB) who had a positive UBT at the point of starting anti-
TB therapy, were included. None had a history of peptic
ulcer disease or had taken antibiotics, bismuth compounds
and/or PPI in the previous month. 14C-UBT was repeated
at the end of the second month and the end of treatment
period and one month after completion of treatment course.
RESULTS: Thirty-five patients (23 males) were enrolled.
14C-UBT was negative in all 35 patients (100%) at the
end of the second month and remained negative in 30
cases (85.7%) at the end of the treatment course. One
month after completion of treatment course, UBT
remained negative in 13 patients (37.1%).
CONCLUSION: Our report underscores the need for
caution while interpreting urea breath test results in
patients undergoing anti-TB therapy. Furthermore, the
combination of drugs used in this study resulted in H pylori
eradication in a minority of patients.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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Helicobacter pylori (H pylori) is the most renowned factor
among peptic ulcer risk factors[1]. Eradication of  this germ
has contributed to a significant reduction in the peptic ulcer
prevalence[2-5]. Several drug regimens have been introduced
for H pylori eradication[6,7]. Urea Breath Test (UBT) is currently
the standard means of  determining H pylori eradication.
Some drugs, including antibiotics are known to lower the
accuracy of this test. In the present study, we evaluated
specifically the effect of a four-agent anti-tuberculosis
therapy on the results of 14C-UBT in a group of patients
with tuberculosis and positive baseline UBT.
MATERIALS AND METHODS
All patients referred to Amir-Alam General Hospital from
January 2002 to December 2003 with a diagnosis of
tuberculosis (TB) were evaluated. TB had been documented
based on clinical and laboratory findings and anti-tuberculosis
treatment was ordered for all of them. Patients with a history
of documented peptic ulcer before treatment or using
Bismuth, proton pump inhibitors (PPIs), H2 blocker agents
or antibiotics in the month before were excluded from the
study. None of the enrolled patients had ever been treated
for H pylori eradication or undergone gastric resection. UBT
test was done for all patients at the time of starting anti-TB
therapy and patients with positive tests were enrolled. The
anti-TB regimen in all patients consisted of Isoniazid,
Rifampicin, Ethambutol and Pyrazinamide for two months,
after which the latter two drugs were stopped and the
treatment was carried on with Isoniazid/Rifampicin until
the end of the treatment course. Cases of spinal tuberculosis
were planned for a 12-mo course of therapy, whereas a 6-mo
course was considered for other types of tuberculous organ
involvement.
14C-UBT was repeated three times for every enrolled patient:
(1) at 2 mo (time of stopping Ethambutol/Pyrazinamide); (2)
end of treatment course (mo 12 for spinal TB cases); (3)
one month after completion of the anti-TB treatment course.
The tests were all performed in the Nuclear Medicine
Laboratory, Shariati Hospital, Tehran University of  Medical
Sciences, by a single team of specialized staff. Each overnight
fasting patient was given 1 Ci (37 kBq) of 14C-urea
dissolved in 250 mL water, after thorough brushing. Breath
samples were collected once before ingestion of the tracer
and subsequently at 15 min after ingestion. The breath
samples were trapped in 1 mmoL ethanolic hyamine
hydroxide in 10 mL toluene-based scintillation fluid. Carbon-
14 content was measured in disintegration per minute
(DPM) mode using a liquid beta-scintillation counter. A cut-
off value of 200 was set for the positive test result.
Intermediate test result was defined as 50-200 DPM, and
test results of <50 DPM were considered negative.
RESULTS
During the study period, 44 patients with a definite diagnosis
of tuberculous infection were planned for anti-TB therapy.
Three patients revealed a history of antibiotic therapy during
the month before and were therefore excluded. Six more
patients had negative or intermediate UBT results and were
also excluded. Thirty-five patients including 23 males (age
17-55 years; mean age: 38.5) and 12 females (age 16-39 years;
mean age: 24) were eligible for the study. Among the enrolled
patients there were 12 pulmonary and 23 extra-pulmonary
cases of TB including 5 patients with a diagnosis of vertebral
tuberculous osteomyelitis (Table 1). None were critically ill
or under treatment with immunosuppressive drugs.
At the end of the second month of therapy, UBT became
negative in all 35 patients (100%). The test results at the
end of the treatment course were still negative in 30 cases
(85.7%). One month after completion of anti-tuberculosis
therapy, UBT turned positive in 17 of 30 patients, so 22
patients (62.9%) had positive results at this point, and the
test remained negative in 13 patients (37.1%, Table 2).
DISCUSSION
H pylori is a slow-growing, microaerophilic, gram-negative
bacterium, whose most striking biochemical characteristic
is the abundant production of urease. This bacterium
colonizes gastric mucosa and elicits both inflammatory and
immune lifelong responses, with release of various bacterial
and host-dependent cytotoxic substances[8]. H pylori eradication
can be established reliably by histology, rapid urease testing
and the urea breath test (UBT). The UBT uses labeled urea
(13C or 14C) that, in the presence of H pylori, is metabolized
by urease to yield CO2. The labeled gas is absorbed across
the gastric mucosa and subsequently measured in the
patient’s expired breath.
Analysis of the results reported in studies in which urea
breath-tests were evaluated against an accepted gold
standard, confirms the great accuracy (sensitivity 97%;
specificity 95%) of this technique[9].
There is general consensus[10-13] regarding the adverse
effect of proton pump inhibitors (PPIs) on the UBT (false
negative results range from 17% to 61%). Moreover,
antibiotics and bismuth compounds reduce H pylori load
such that infection may be undetectable. Thus, urea breath-
tests should not be performed within 4 wk of  receiving
such drugs, whether given specifically to treat the infection
or not[14].
In 1992, Mitchell found that a history of pulmonary
TB might be associated with an increased prevalence of
H pylori infection[15]. More recently, Woeltje assessed the
prevalence of tuberculin skin test (TST) positivity in a cohort
of 346 newly hospitalized patients. A history of peptic ulcer
disease was one of the identified risk factors for a positive
TST test (odds ratio: 4.53, P = 0.017)[16]. Increased risk of
TB for persons with a history of peptic ulcer disease has
also been reported[17]. H pylori is seen in high prevalence in
some populations around the world[18] especially in regions
having lower socioeconomic status[19-21]. The same is true for
the distribution of tuberculosis which is, to a great extent,
clustered in some developing countries[22]. Rationally, there
seems to exist a population of considerable size, potentially
exposed to both microorganisms.
In-vitro studies of Rifampicin and Streptomycin, two
drugs commonly used in anti-tuberculosis regimens have
suggested the efficacy of  these agents against H pylori[23-25]
and a decrease in H pylori seroprevalence during anti-tuberculosis
therapy has been reported[26]. There is no report of using
Rifampicin in H pylori eradication regimens but recently Rifabutin
from the same family of agents has been implemented as
rescue therapy against resident species in combination with
Pantoprazole and Amoxicillin[27]. Isoniazid is used in treating
mycobacterial species and acts via inhibiting mycolic acid
synthesis. There is no report so far of the efficacy of this
agent on non-mycobacterial microorganisms[28].
To our knowledge, there has been no specific report of
the effect of anti-tuberculosis therapy on the accuracy of
UBT. Our report shows that anti-TB therapy causes negative
UBT results in a considerable fraction of patients, and so
underscores the need for caution while interpreting urea
breath test results in patients undergoing anti-TB therapy.
Table 2  14C-urea breath test results among 35 patients during the course of anti-tuberculosis therapy
Baseline End of 2nd mo of therapy End of treatment course        One month after completion on therapy
Positive (%) 35 (100)    0 (0)                   4 (11.4) 22 (62.9)
Negative (%)    0 (0) 35 (100)                30 (85.7) 13 (37.1)
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Table 1  Patient characteristics
Gender Male         23 (65.7%)
Female         12 (34.3%)
Total 35
Age (yr) Male    17-55 (38.5±11.2)
Female    16-39 (24.0±8.6)
Type of infection Pulmonary TB 12
TB adenitis   9
TB enteritis   5
TB osteomyelitis (vertebra)   5
Meningeal TB   2
Peritoneal TB   2
Total 35
Furthermore, the combination of  drugs used in this study
resulted in H pylori eradication in a minority of patients.
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